A Phase II, Multicentre, Double-blind, Randomised, Placebo Controlled, Dose Escalation and Dose Finding Study to Evaluate the Efficacy and Safety of Dysport in Vulvodynia Patients
Latest Information Update: 06 May 2025
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Vulvodynia
- Focus Adverse reactions; Therapeutic Use
- Acronyms DYVINIA
- Sponsors Ipsen
Most Recent Events
- 15 Apr 2025 Results(n=60) evaluating optimal doses of Dysport and evaluate its efficacy and safety compared with placebo published in the Journal of Sexual Medicine.
- 29 Jan 2021 Status changed from active, no longer recruiting to discontinued.
- 25 Nov 2020 Planned End Date changed from 31 Dec 2022 to 31 Jan 2021.